Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 2/20 | 0.62 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.62 |
| ▸ | NPBWR1 | P48145 | 9/20 | 0.60 |
| ▸ | ERAP2 | Q6P179 | 6/20 | 0.56 |
| ▸ | ECE1 | P42892 | 2/20 | 0.54 |
| ▸ | IL1RN | P18510 | 6/20 | 0.53 |
| ▸ | ERAP1 | Q9NZ08 | 3/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29376430 | 0.96 | OPRM1 (0.61) | OPRM1OPRD1NPBWR1ERAP2ECE1 | |
| SCHEMBL30538857 | 0.95 | ECE1 (0.57) | OPRM1OPRD1NPBWR1ERAP2ECE1 | |
| SCHEMBL30576704 | 0.92 | OPRM1 (0.68) | OPRM1OPRD1NPBWR1ERAP2IL1RN | |
| SCHEMBL30576711 | 0.92 | OPRM1 (0.68) | OPRM1OPRD1NPBWR1ERAP2IL1RN | |
| SCHEMBL30052459 | 0.91 | ECE1 (0.61) | OPRM1OPRD1ERAP2ECE1IL1RN | |
| SCHEMBL29794167 | 0.89 | OPRM1 (0.62) | OPRM1OPRD1ERAP2ECE1 | |
| SCHEMBL29872607 | 0.89 | OPRM1 (0.62) | OPRM1OPRD1ERAP2ECE1 | |
| SCHEMBL9868659 | 0.89 | OPRM1 (0.66) | OPRM1OPRD1ECE1 | |
| SCHEMBL29391520 | 0.89 | OPRM1 (0.66) | OPRM1OPRD1ECE1 | |
| Trifluoroacetic Acid SCHEMBL30576699 | 0.89 | OPRD1 (0.64) | OPRM1OPRD1NPBWR1ERAP2IL1RN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4171662-A1 | SELECTIVE GIP RECEPTOR AGONISTS COMPRISING A CHELATING MOIETY FOR IMAGING AND THERAPY PURPOSES | Antaros Medical AB (SE) | 2023-05-03 | — | — | EP | claimed |
| US-20230127047-A1 | SELECTIVE GIP RECEPTOR AGONISTS COMPRISING A CHELATING MOIETY FOR IMAGING AND THERAPY PURPOSES | ANTAROS MEDICAL AB (SE) | 2023-04-27 | — | — | US | claimed |
| EP-4171662-A1 | SELECTIVE GIP RECEPTOR AGONISTS COMPRISING A CHELATING MOIETY FOR IMAGING AND THERAPY PURPOSES | Antaros Medical AB (SE) | 2023-05-03 | — | — | EP | disclosed |
| US-20230127047-A1 | SELECTIVE GIP RECEPTOR AGONISTS COMPRISING A CHELATING MOIETY FOR IMAGING AND THERAPY PURPOSES | ANTAROS MEDICAL AB (SE) | 2023-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230127047-A1 | SELECTIVE GIP RECEPTOR AGONISTS COMPRISING A CHELATING MOIETY FOR IMAGING AND THERAPY PURPOSES | GIPR, GRPR, GLP1R | OPRM1 506/4885OPRD1 1019/4885NPBWR1 75/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.